LONG-TERM INCENTIVE PLANS LTIPS The details of the LTIP scheme are provided in Note 35.
As at 31 December 2012, the total number of awards granted to employees of the Company under the LTIPs during the life of the plans was 1,331,000 shares 2011: 1,123,000 and the total amount of the compensation expenses charged to profit and loss is $1,744,000 2011: $1,818,000.
MANAGEMENT INCENTIVE PLANS MIPS The details of the MIPs scheme are provided in Note 35.
As at 31 December 2012, the total number of awards granted to employees of the Company under the MIPs during the life of the plans was 4,000 shares 2011: Nil and the total amount of the compensation expenses charged toprot and loss is $11,000 2011: $Nil.
SHARE CAPITAL 2012 2011 Issued and fully paid included in shareholders equity: $000 $000 197,036,507 2011: 195,851,307 Ordinary Shares of 10p each 35,091 34,904 Details of the issue of share capital in the year are given in Note 30.
SHARE PREMIUM Share premium $000 Balance at 1 January 2012 278,094 Premium arising on exercise of stock options 1,022 Balance at 31 December 2012 279,116 56.
NET INCOME FOR THE YEAR As permitted by section 408 of the Companies Act 2006, the statement of comprehensive income of the Company is not presented as part ofthese accounts.
Included in the net income for the year is an amount of $614,422,000 2011: $75,557,000 representing dividends received and $1,744,000 2011: $1,818,000 representing the current year charge of LTIPs and $11,000 2011: $Nil representing the current year charge of MIPsexpenses relating to the Companys employees.
The remaining $6,206,000 2011: $5,689,000 of the Groups stock options, LTIPs and MIPs charge is recharged to subsidiary companies.
RELATED PARTY Darhold Limited: is a related party of the Company because it is considered one of the major shareholders of Hikma Pharmaceuticals PLC with ownership percentage of 29.0% at the end of 2012 2011: 29.2%.
Further details on the relationship between Mr. Samih Darwazah, Mr. SaidDarwazah, Mr. Mazen Darwazah and Mr. Ali Al-Husry, and Darhold Limited are given in the Directors Report.
Amounts repayable to and from subsidiaries are disclosed in Notes 44 and 47.
Other transactions with related parties include management charges for services provided to the subsidiary companies, equity settled employee share scheme costs relating to the subsidiary companies and transactions with key management personnel.
Compensation paid to keymanagement personnel is disclosed in Note 37.
Details of Directors remuneration are disclosed in the Remuneration Committee Report on pages 82 to 103.
More details on the general information of the ultimate parent of the Group are disclosed in Note 2.
HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012 163
